​

Funding Round

Series A - Aeglea BioTherapeutics

Series A - Aeglea BioTherapeutics

Investment Firm

Overview

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Announced Date

Feb 06, 2014

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Lilly Ventures

Lilly Ventures

Lilly Ventures is a convertible_note and early_stage_venture and late_stage_venture and seed firm.

Participant Investors

4

Investor Name
Participant InvestorKBI Biopharma
Participant InvestorUT Horizon Fund
Participant InvestorLilly Ventures
Participant InvestorNovartis Venture Fund

Round Details and Background

Aeglea BioTherapeutics raised $12000000 on 2014-02-06 in Series A

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 22, 2023
Post-IPO Equity - Aeglea BioTherapeutics
-210.0M
Mar 23, 2015
Series B - Aeglea BioTherapeutics
11-44.0M
Feb 06, 2014
Series A - Aeglea BioTherapeutics
4-12.0M

Recent Activity

There is no recent news or activity for this profile.